{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:13:43Z","timestamp":1784272423374,"version":"3.55.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC1141\/PPI\/SY\/104990"],"award-info":[{"award-number":["BRC1141\/PPI\/SY\/104990"]}],"id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC1141\/PPI\/SY\/104990"],"award-info":[{"award-number":["BRC1141\/PPI\/SY\/104990"]}],"id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Consumption of gabapentinoids has increased worldwide in recent years, and the association between its use and drug poisoning is of public health concern. This study aimed to investigate the association between gabapentinoid treatment and the risk of drug poisoning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>In this within-individual study, we utilised data from the United Kingdom (UK) Clinical Practice Research Datalink (CPRD) Aurum database linked to the Hospital Episode Statistics (HES) and Office for National Statistics (ONS). The analysis included individuals aged 18 or above who were prescribed gabapentinoids and had an incident all-cause drug poisoning event between 1st January 2010 and 31st December 2020. Using the self-controlled case series (SCCS) design, we assessed the risk of drug poisoning incidence in predefined risk periods: 90 days before treatment initiation, first 28, 29\u201356, 57\u201384 days, and the remaining treatment time. Concomitant use with opioids\/benzodiazepines was also evaluated. Adjusted incidence rate ratios (aIRRs) were calculated using conditional Poisson regression. A case-case-time-control (CCTC) analysis was also conducted, with adjusted odds ratio (aOR) calculated to validate the findings from the main SCCS analysis. All analyses have adjusted for key time-varying confounders, including age, season, and concomitant use of opioids, antiseizure medications, psychotropic medications, and non-steroidal anti-inflammatory drugs (NSAIDs).<\/jats:p>\n                    <jats:p>\n                      16,827 individuals met the inclusion criteria and were included in the SCCS analysis. The risk of drug poisoning, compared with the reference periods, increased during the first 28 days of gabapentinoid treatment (aIRR\u2009=\u20091.81, 95% confidence interval [CI] [1.66, 1.99];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), eventually dropped to 1.11 (95% CI [1.05, 1.17];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in the remainder of the treatment period. Notably, the risk was doubled during the 90-day preceding treatment initiation (aIRR\u2009=\u20092.09, 95% CI [1.98, 2.21];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Co-administration with opioids elevated the risk by 30%, while benzodiazepines increased it 2-fold. The CCTC analysis also detected an increased aOR of 1.36 (95% CI [1.12, 1.65];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) of receiving gabapentinoid treatment within 30 days prior to a drug poisoning event. The SCCS approach cannot completely exclude the effect of unmeasured time-varying confounders, such as transient changes in socioeconomic status, major life events, or illicit drug use, although the negative control analysis did not suggest meaningful residual confounding.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results suggest that gabapentinoid is associated with an increased risk of drug poisoning. Close monitoring throughout gabapentinoid treatment journey for drug poisoning is needed, especially at the initial phase. Concomitant use with opioid or benzodiazepines should be avoided.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1005035","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:36:59Z","timestamp":1776361019000},"page":"e1005035","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between gabapentinoid treatment, concurrent use with opioid or benzodiazepine and the risk of drug poisoning: A self-controlled case series study"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4850-566X","authenticated-orcid":true,"given":"Andrew S. C.","family":"Yuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-5181","authenticated-orcid":true,"given":"Boqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3011-8320","authenticated-orcid":true,"given":"Adrienne Y. L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-3862","authenticated-orcid":true,"given":"Joseph F.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P. J.","family":"Osborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-7933","authenticated-orcid":true,"given":"Frank M. C.","family":"Besag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-0470","authenticated-orcid":true,"given":"Wallis C. Y.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":true,"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-7267","authenticated-orcid":true,"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-1942","authenticated-orcid":true,"given":"Kenneth K. C.","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"9","key":"pmed.1005035.ref001","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1073\/pnas.0708930105","article-title":"Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin","volume":"105","author":"J Hendrich","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"pmed.1005035.ref002","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A clinical overview of off-label use of gabapentinoid drugs","volume":"179","author":"CW Goodman","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"1","key":"pmed.1005035.ref003","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1038\/s41467-023-40637-8","article-title":"Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study","volume":"14","author":"AYL Chan","year":"2023","journal-title":"Nat Commun"},{"issue":"24","key":"pmed.1005035.ref004","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1001\/jama.2022.10100","article-title":"Gabapentin increasingly implicated in overdose deaths","volume":"327","author":"BM Kuehn","year":"2022","journal-title":"JAMA"},{"key":"pmed.1005035.ref005","first-page":"28","article-title":"Benzodiazepine use, abuse, and dependence","author":"CP O\u2019brien","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"15","key":"pmed.1005035.ref006","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain \u2013 United States, 2016","volume":"315","author":"D Dowell","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"pmed.1005035.ref007","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain \u2013 is increased prescribing a cause for concern?","volume":"377","author":"CW Goodman","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"pmed.1005035.ref008","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"RV Smith","year":"2016","journal-title":"Addiction"},{"issue":"19","key":"pmed.1005035.ref009","doi-asserted-by":"crossref","first-page":"664","DOI":"10.15585\/mmwr.mm7119a3","article-title":"Notes from the field: trends in gabapentin detection and involvement in drug overdose deaths - 23 states and the District of Columbia, 2019-2020","volume":"71","author":"CL Mattson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"pmed.1005035.ref010","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/add.13843","article-title":"Risk to heroin users of polydrug use of pregabalin or gabapentin","volume":"112","author":"A Lyndon","year":"2017","journal-title":"Addiction"},{"issue":"3","key":"pmed.1005035.ref011","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bcp.15073","article-title":"Pregabalin poisoning: evaluation of dose-toxicity relationship","volume":"88","author":"SJ Rietjens","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"pmed.1005035.ref012","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1111\/bcp.14348","article-title":"Pregabalin poisoning and rising recreational use: a retrospective observational series","volume":"86","author":"KZ Isoardi","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"pmed.1005035.ref013","article-title":"Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden","volume":"365","author":"Y Molero","year":"2019","journal-title":"BMJ"},{"key":"pmed.1005035.ref014","first-page":"100302","article-title":"Adverse outcomes associated with concurrent gabapentin, opioid, and benzodiazepine utilization: a nested case-control study","volume":"13","author":"A Olopoenia","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"12","key":"pmed.1005035.ref015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.31647","article-title":"Association of gabapentinoids with the risk of opioid-related adverse events in surgical patients in the United States","volume":"3","author":"K Bykov","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"pmed.1005035.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study","volume":"14","author":"T Gomes","year":"2017","journal-title":"PLoS Med"},{"key":"pmed.1005035.ref017","unstructured":"Datalink CPR. CPRD Aurum May 2022 dataset: clinical practice research datalink. 2022 [cited 2024 June 04]. Available from: https:\/\/www.cprd.com\/cprd-aurum-may-2022-dataset"},{"issue":"6","key":"pmed.1005035.ref018","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"A Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"3","key":"pmed.1005035.ref019","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"E Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"5","key":"pmed.1005035.ref020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1592\/phco.23.5.686.32205","article-title":"Validity of the general practice research database","volume":"23","author":"SS Jick","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"1","key":"pmed.1005035.ref021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the General Practice Research Database: a systematic review","volume":"69","author":"E Herrett","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"pmed.1005035.ref022","unstructured":"CPRD. CPRD linked data: Medicines and Healthcare Products Regulatory Agency. 2023 [cited 2023 Sep 20]. Available from: https:\/\/cprd.com\/cprd-linked-data#HES%20Admitted%20Patient%20Care%20data"},{"issue":"10","key":"pmed.1005035.ref023","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/sim.2302","article-title":"Tutorial in biostatistics: the self-controlled case series method","volume":"25","author":"HJ Whitaker","year":"2006","journal-title":"Stat Med"},{"key":"pmed.1005035.ref024","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"I Petersen","year":"2016","journal-title":"BMJ"},{"issue":"10","key":"pmed.1005035.ref025","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamapsychiatry.2017.2183","article-title":"Association of risk of suicide attempts with methylphenidate treatment","volume":"74","author":"KKC Man","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"pmed.1005035.ref026","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s44220-022-00008-6","article-title":"Attention deficit hyperactivity disorder, physical abuse and methylphenidate treatment in children","volume":"1","author":"KKC Man","year":"2023","journal-title":"Nat Mental Health"},{"issue":"4","key":"pmed.1005035.ref027","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(21)00007-4","article-title":"Periods of altered risk for non-fatal drug overdose: a self-controlled case series","volume":"6","author":"C Keen","year":"2021","journal-title":"Lancet Public Health"},{"key":"pmed.1005035.ref028","article-title":"Use of gabapentinoid treatment and the risk of self-harm: population based self-controlled case series study","volume":"389","author":"ASC Yuen","year":"2025","journal-title":"BMJ"},{"key":"pmed.1005035.ref029","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a1069","article-title":"The self controlled case series method","volume":"337","author":"H Whitaker","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"pmed.1005035.ref030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jnci\/djaa122","article-title":"Opioid use disorder and overdose in older adults with breast, colorectal, or prostate cancer","volume":"113","author":"AW Roberts","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"pmed.1005035.ref031","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamaneurol.2018.0333","article-title":"Risk of unnatural mortality in people with epilepsy","volume":"75","author":"HC Gorton","year":"2018","journal-title":"JAMA Neurol"},{"key":"pmed.1005035.ref032","unstructured":"World Health Organization. Defined Daily Dose (DDD) [cited 2022 Nov 29]. Available from: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd"},{"issue":"4","key":"pmed.1005035.ref033","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/003335491513000411","article-title":"Drug overdose deaths: let\u2019s get specific","volume":"130","author":"S Slavova","year":"2015","journal-title":"Public Health Rep"},{"issue":"2","key":"pmed.1005035.ref034","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(21)00254-1","article-title":"Causes of death among people who used illicit opioids in England, 2001-18: a matched cohort study","volume":"7","author":"D Lewer","year":"2022","journal-title":"Lancet Public Health"},{"key":"pmed.1005035.ref035","volume-title":"Deaths related to drug poisoning in England and Wales QMI","author":"Statistics OfN","year":"2020"},{"issue":"7","key":"pmed.1005035.ref036","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40263-021-00824-x","article-title":"Treatment with methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the risk of all-cause poisoning in children and adolescents: a self-controlled case series study","volume":"35","author":"L Gao","year":"2021","journal-title":"CNS Drugs"},{"issue":"1","key":"pmed.1005035.ref037","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/EDE.0000000000001110","article-title":"Record linkage approaches using prescription drug monitoring program and mortality data for public health analyses and epidemiologic studies","volume":"31","author":"S Nechuta","year":"2020","journal-title":"Epidemiology"},{"issue":"8","key":"pmed.1005035.ref038","doi-asserted-by":"crossref","first-page":"3000605231192779","DOI":"10.1177\/03000605231192779","article-title":"Differences of chronological seasonality in drug overdose","volume":"51","author":"C-H Lo","year":"2023","journal-title":"J Int Med Res"},{"issue":"5","key":"pmed.1005035.ref039","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41591-020-0855-y","article-title":"Age and generational patterns of overdose death risk from opioids and other drugs","volume":"26","author":"H Jalal","year":"2020","journal-title":"Nat Med"},{"key":"pmed.1005035.ref040","article-title":"Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study","volume":"360","author":"GA Brat","year":"2018","journal-title":"BMJ"},{"issue":"494","key":"pmed.1005035.ref041","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1198\/jasa.2011.ap10108","article-title":"Self-controlled case series analysis with event-dependent observation periods","volume":"106","author":"CP Farrington","year":"2011","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"pmed.1005035.ref042","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/biostatistics\/kxn013","article-title":"Case series analysis for censored, perturbed, or curtailed post-event exposures","volume":"10","author":"CP Farrington","year":"2009","journal-title":"Biostatistics"},{"issue":"4","key":"pmed.1005035.ref043","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/sim.7536","article-title":"Investigating the assumptions of the self-controlled case series method","volume":"37","author":"HJ Whitaker","year":"2018","journal-title":"Stat Med"},{"issue":"4","key":"pmed.1005035.ref044","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/EDE.0b013e31821d09cd","article-title":"Future cases as present controls to adjust for exposure trend bias in case-only studies","volume":"22","author":"S Wang","year":"2011","journal-title":"Epidemiology"},{"issue":"7624","key":"pmed.1005035.ref045","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"E von Elm","year":"2007","journal-title":"BMJ"},{"issue":"4","key":"pmed.1005035.ref046","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00127-021-02199-2","article-title":"Mental disorder and opioid overdose: a systematic review","volume":"57","author":"J van Draanen","year":"2022","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"1","key":"pmed.1005035.ref047","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/ADM.0000000000000451","article-title":"Alcohol and drug overdose and the influence of pain conditions in an addiction treatment sample","volume":"13","author":"AC Fernandez","year":"2019","journal-title":"J Addict Med"},{"issue":"4","key":"pmed.1005035.ref048","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jpsychires.2010.09.005","article-title":"Sleep problems, suicidal ideation, and self-harm behaviors in adolescence","volume":"45","author":"MM Wong","year":"2011","journal-title":"J Psychiatr Res"},{"issue":"12","key":"pmed.1005035.ref049","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? A systematic review","volume":"27","author":"U Bonnet","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"19","key":"pmed.1005035.ref050","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1002\/sim.7311","article-title":"Spline-based self-controlled case series method","volume":"36","author":"Y Ghebremichael-Weldeselassie","year":"2017","journal-title":"Stat Med"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:37:12Z","timestamp":1776361032000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005035"}},"subtitle":[],"editor":[{"given":"Seena","family":"Fazel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1005035","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}